STOCKHOLM, Sweden, June 12, 2003 (PRIMEZONE) -- Straumann AG Holdings ("Straumann") has announced that it has acquired approximately 91 percent of the Ordinary Shares of Biora AB pursuant to its public offer. Straumann has called for the compulsory acquisition of the remaining outstanding Biora Ordinary Shares. Accordingly, the Biora Board has decided to refer the compulsory acquisition matter to an arbitration board. The Board of Biora has also decided to submit an application for de-listing Biora's Ordinary Shares from the "O-list" of the Stockholm Stock Exchange ("SSE"). Information regarding the last trading day for Biora's Ordinary Shares on the SSE will be announced at a later date.
Malmo, June 12th 2003 The Board of Biora AB Per Wahlstrom, Chairman of the Board
Biora develops manufactures and sells biotechnology-based products to dentists. Its principal product, Emdogain(r)Gel, which is approved for sale in Europe, North America and Japan among others, naturally regenerates tooth-supporting structure that the tooth has lost due to periodontitis. Biora's shares are listed on the "O-list" of the Stockholm Stock Exchange in Sweden.
This press release may contain certain forward- looking statements that relate to future events or future business and financial performance. Such statements can only be predictions and the actual events or results may differ from those discussed. The Company cautions that these statements are subject to important factors that could cause actual results to differ materially from those expressed or implied in such forward looking statements and are more fully discussed in periodic reports filed with Securities and Exchange Commission.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2003/06/12/20030612BIT00050/wkr0001.doc
http://www.waymaker.net/bitonline/2003/06/12/20030612BIT00050/wkr0002.pdf